Structure Therapeutics' Phase 1b Multiple Ascending Dose Study
Of Its GSBR-1290, In Healthy Overweight Or Obese Individuals.
Demonstrated Significant Weight Loss Supporting Once-daily Dosing
And An Encouraging Safety And Tolerability Profile
Structure Therapeutics Announced A Private Placement Of 21.6M
Shares And 2.4M Newly Designated Non-voting Shares At $12.49/Share,
With Gross Proceeds Of Approximately $300M
GPCR
2 nice setups from Wednesday's newsletter
Posted by steve on 29th of Sep 2023 at 08:25 am
Structure Therapeutics' Phase 1b Multiple Ascending Dose Study Of Its GSBR-1290, In Healthy Overweight Or Obese Individuals. Demonstrated Significant Weight Loss Supporting Once-daily Dosing And An Encouraging Safety And Tolerability Profile
Structure Therapeutics Announced A Private Placement Of 21.6M Shares And 2.4M Newly Designated Non-voting Shares At $12.49/Share, With Gross Proceeds Of Approximately $300M
very nice sold half, thanks,
Posted by morton7 on 29th of Sep 2023 at 08:31 am
very nice sold half, thanks, you two take the rest of the day off! :-)
awesome! that's basically what I
Posted by matt on 29th of Sep 2023 at 09:17 am
awesome! that's basically what I did, sold 1/2